• 1
    Abe K, Inchauspe G, Shikata T, Prince AM. Three different patterns of hepatitis C virus infection in chimpanzees. HEPATOLOGY 1992; 15: 690-695.
  • 2
    Zhao XU, Tang ZY, Klumpp B, Wolff-Vorbeck G, Barth H, Levy S, et al. Primary hepatocytes of Tupaia belangeri as a potential model for hepatitis C virus infection. J Clin Invest 2002; 109: 221-232.
  • 3
    Azuma H, Paulk N, Ranade A, Dorrell C, Al-Dhalimy M, Ellis E, et al. Robust expansion of human hepatocytes in Fah(–/–)/Rag2(–/–)/Il2rg(–/–) mice. Nat Biotechnol 2007; 25: 903-910.
  • 4
    Bissig KD, Wieland SF, Tran P, Isogawa M, Le TT, Chisari FV, et al. Human liver chimeric mice provide a model for hepatitis B and C virus infection and treatment. J Clin Invest 2010; 120: 924-930.
  • 5
    Kato T, Date T, Miyamoto M, Furusaka A, Tokushige K, Mizokami M, et al. Efficient replication of the genotype 2a hepatitis C virus subgenomic replicon. Gastroenterology 2003; 125: 1808-1817.
  • 6
    Wakita, T, Pietschmann, T, Kato T, Date T, Miyamoto M, Zhao Z, et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 2005; 11: 791-796.
  • 7
    Pietschmann T, Kaul A, Koutsoudakis G, Shavinskaya A, Kallis S, Steinmann E, et al. Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras. Proc Natl Acad Sci U S A 2006; 103: 7408-7413.
  • 8
    Lindenbach BD, Evans MJ, Syder AJ, Wolk B, Tellinghuisen TL, Liu CC, et al. Complete replication of hepatitis C virus in cell culture. Science 2005; 309: 623-626.
  • 9
    Zhong J, Gastaminza P, Cheng G, Kapadia S, Kato T, Burton DR, et al. Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci U S A 2005; 102: 9294-9299.
  • 10
    Molina S, Castet V, Pichard-Garcia L, Wychowski C, Meurs E, Pascussi JM, et al. Serum-derived hepatitis C virus infection of primary human hepatocytes is tetraspanin CD81 dependent. J Virol 2008; 82: 569-574.
  • 11
    Ploss A, Khetani SR., Jones CT, Syder AJ, Trehan K, Gaysinskaya VA, et al. Persistent hepatitis C virus infection in microscale primary human hepatocyte cultures. Proc Natl Acad Sci U S A 2010; 107: 3141-3145.
  • 12
    Podevin P, Carpentier A, Pène V, Aoudjehane L, Carrière M, Zaïdi S, et al. Production of infectious hepatitis C virus in primary cultures of human adult hepatocytes. Gastroenterology 2010; 139: 1355-1364.
  • 13
    Banaudha K, Orenstein JM, Korolnek T, St Laurent GC, 3rd, Wakita T, Kumar A, et al. Primary hepatocyte culture supports hepatitis C virus replication: a model for infection-associated hepatocarcinogenesis. HEPATOLOGY 2010; 51: 1922-1932.
  • 14
    Kirby TO, Rivera A, Rein D, Wang M, Ulasov I, Breidenbach M, et al. A novel ex vivo model system for evaluation of conditionally replicative adenoviruses therapeutic efficacy and toxicity. Clin Cancer Res 2004; 10: 8697-8703.
  • 15
    Jung D, Elferink MG, Stellaard F, Groothuis GM. Analysis of bile acid-induced regulation of FXR target genes in human liver slices. Liver Int 2007; 27: 137-144.
  • 16
    Carrière M, Pène V, Breiman A, Conti F, Chouzenoux S, Meurs E, et al. A novel, sensitive, and specific RT-PCR technique for quantitation of hepatitis C virus replication. J Med Virol 2007; 79: 155-160.
  • 17
    Liu L, Yao P, Zhang X, Hao L, Yang X, Sun X. [Effect of acute ethanol exposure on HO-1 enzyme activity in human primary hepatocytes.] [Article in Chinese]. Wei Sheng Yan Jiu 2004; 33: 537-539.
  • 18
    Wu D, Cederbaum AI. Development and properties of HepG2 cells that constitutively express CYP2E1. Methods Mol Biol 2008; 447: 137-150.
  • 19
    Hino H, Tateno C, Sato H, Yamasaki C, Katayama S, Kohashi T, et al. A long-term culture of human hepatocytes which show a high growth potential and express their differentiated phenotypes. Biochem Biophys Res Commun 1999; 256: 184-191.
  • 20
    Runge D, Runge DM, Jäger D, Lubecki KA, Beer Stolz D, Karathanasis S, et al. Serum-free, long-term cultures of human hepatocytes: maintenance of cell morphology, transcription factors, and liver-specific functions. Biochem Biophys Res Commun 2000; 269: 46-53.
  • 21
    Qadri I, Hu LJ, Iwahashi M, Al-Zuabi S, Quattrochi LC, Simon FR. Interaction of hepatocyte nuclear factors in transcriptional regulation of tissue specific hormonal expression of human multidrug resistance-associated protein 2 (abcc2). Toxicol Appl Pharmacol 2009; 234: 281-292.
  • 22
    Korarek TA, Zangar RC, Novak RF. Post-transcriptional regulation of rat CYP2E1 expression: role of CYP2E1 mRNA untranslated regions in control of translational efficiency and message stability. Arch Biochem Biophys 2000; 376: 180-190.
  • 23
    Bergheim I, Bode C, Parlesak A. Distribution of cytochrome P450 2C, 2E1, 3A4, and 3A5 in human colon mucosa. BMC Clin Pharmacol 2005; 5: 1-7.
  • 24
    Zangar RC, Hernandez M, Novak RF. Posttranscriptional elevation of cytochrome P450 3A expression. Biochem Biophys Res Commun 1997; 231: 203-205.
  • 25
    McLauchlan J, Lemberg MK, Hope G, Martoglio B. Intramembrane proteolysis promotes trafficking of hepatitis C virus core protein to lipid droplets. EMBO J 2002; 21: 3980-3988.
  • 26
    McLauchlan J. Properties of the hepatitis C virus core protein: a structural protein that modulates cellular processes. J Viral Hepat 2000; 7: 2-14.
  • 27
    Bartosch B, Dubuisson J, Cosset FL. Infectious hepatitis C virus pseudoparticles containing functional E1-E2 envelope protein complexes. J Exp Med 2003; 197: 633-642.
  • 28
    Logvinoff C, Major ME, Oldach D, Heyward S, Talal A, Balfe P, et al. Neutralizing antibody response during acute and chronic hepatitis C virus infection. Proc Natl Acad Sci U S A 2004; 101: 10149-10151.
  • 29
    Koutsoudakis G, Herrmann E, Kallis S, Bartenschlager R, Pietschmann T. The level of CD81 cell surface expression is a key determinant for productive entry of hepatitis C virus into host cells. J Virol 2007; 81: 588-598.
  • 30
    Owsianka A, Tarr AW, Juttla VS, Lavillette D, Bartosch B, François-Loïc Cosset, et al. Monoclonal antibody AP33 defines a broadly neutralizing epitope on the hepatitis C virus E2 envelope glycoprotein. J Virol 2005; 11095-11104.
  • 31
    Perni RB, Almquist SJ, Byrn RA, Chandorkar G, Chaturvedi PR, Courtney LF, et al. Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease. Antimicrob Agents Chemother 2006; 50: 899-909.
  • 32
    Mathis MJ, Curiel DT. Employment of liver tissue slice analysis to assay hepatotoxicity linked to replicative and nonreplicative adenoviral agents. Cancer Gene Ther 2006; 6: 606-618.
  • 33
    Khetani SR, Bhatia SN. Microscale culture of human liver cells for drug development. Nat Biotech 2008; 18: 120-126.
  • 34
    Lu W, Ou JH. Phosphorylation of hepatitis C virus core protein by protein kinase A and protein kinase C. Virology 2002; 300: 20-30.
  • 35
    Lindenbach BD, Meuleman P, Ploss A, Vanwolleghem T, Syder AJ, McKeating JA, et al. Cell culture-grown hepatitis C virus is infectious in vivo and can be recultured in vitro. Proc Natl Acad Sci U S A 2006; 103: 3805-3809.
  • 36
    Aizaki H, Morikawa K, Fukasawa M, Hara H, Inoue Y, Tani H, et al. Critical role of virion-associated cholesterol and sphingolipid in hepatitis C virus infection. J Virol 2008; 82: 5715-5724.
  • 37
    Preiss S, Thompson A, Chen X, Rodgers S, Markovska V, Desmond P, et al. Characterization of the innate immune signaling pathways in hepatocyte cell lines. J Viral Hepat 2008; 15: 888-900.
  • 38
    Li K, Chen Z, Kato N, Gale M, Jr., Lemon SM. Distinct poly (I-C) and virus activated signaling pathways leading to interferon-beta production in hepatocytes. J Biol Chem 2005; 280: 16739-16747.
  • 39
    Parrish AR, Gandolfi AJ, Brendel K. Precision-cut tissue slices: applications in pharmacology and toxicology. Life Sci 1995; 57: 1887-1901.
  • 40
    Chevaliez S, Pawlotsky JM. Hepatitis C virus: virology, diagnosis, and management of antiviral therapy. World J Gastroenterol 2007; 13: 2461-2466.